Richard B Lanman Selected Research

Lung Neoplasms (Lung Cancer)

1/2020	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
9/2019	BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.
1/2019	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
11/2018	The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
1/2018	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.
1/2018	Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.
12/2017	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
11/2017	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
1/2017	Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.
10/2016	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard B Lanman Research Topics

Disease

55	Neoplasms (Cancer) 01/2022 - 01/2015
18	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 10/2016
10	Lung Neoplasms (Lung Cancer) 01/2020 - 10/2016
8	Breast Neoplasms (Breast Cancer) 07/2021 - 10/2017
7	Colorectal Neoplasms (Colorectal Cancer) 10/2019 - 01/2018
6	Disease Progression 01/2020 - 10/2017
3	Carcinoma (Carcinomatosis) 10/2020 - 01/2017
3	Neoplasm Metastasis (Metastasis) 09/2020 - 11/2017
3	Adenocarcinoma of Lung 01/2020 - 09/2017
3	Stomach Neoplasms (Stomach Cancer) 01/2020 - 01/2019
3	Colonic Neoplasms (Colon Cancer) 01/2020 - 01/2019
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2018
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 07/2017
2	Hypersensitivity (Allergy) 01/2020 - 12/2018
2	Microsatellite Instability 12/2019 - 01/2019
2	Adenocarcinoma 12/2019 - 01/2018
2	Hepatocellular Carcinoma (Hepatoma) 10/2019 - 01/2018
2	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 01/2018
2	Thyroid Neoplasms (Thyroid Cancer) 01/2015 - 12/2013
2	Thyroid Nodule (Nodule, Thyroid) 01/2015 - 12/2010
2	Coronary Disease (Coronary Heart Disease) 07/2006 - 01/2006
1	Cholangiocarcinoma 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Appendiceal Neoplasms (Appendix Cancer) 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2019
1	Nausea 10/2019
1	Thrombocytopenia (Thrombopenia) 10/2019
1	Fatigue 10/2019
1	Dehydration (Water Stress) 10/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Urogenital Neoplasms 01/2019
1	Turcot syndrome 01/2019
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2019
1	Brain Neoplasms (Brain Tumor) 01/2019
1	Peritoneal Neoplasms 08/2018
1	Melanoma (Melanoma, Malignant) 01/2018
1	Neuroblastoma 01/2018

Drug/Important Bio-Agent (IBA)

42	Circulating Tumor DNAIBA 01/2022 - 01/2015
28	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2015
18	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2015
9	Biomarkers (Surrogate Marker)IBA 11/2021 - 07/2006
4	Tyrosine Kinase InhibitorsIBA 01/2020 - 12/2018
3	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2019
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 12/2018
3	neratinibIBA 01/2020 - 10/2017
3	Phosphotransferases (Kinase)IBA 01/2020 - 01/2019
3	NucleotidesIBA 01/2020 - 01/2018
3	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2018
2	HM781-36BIBA 03/2020 - 10/2019
2	Estrogen ReceptorsIBA 01/2020 - 01/2019
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020 - 01/2019
2	Neurofibromin 1 (Neurofibromin)IBA 01/2020 - 01/2019
2	ElectrolytesIBA 01/2020 - 10/2019
2	alectinibIBA 11/2019 - 01/2018
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2019 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2018
2	CrizotinibIBA 12/2018 - 11/2017
2	Messenger RNA (mRNA)IBA 01/2018 - 12/2010
2	Anaplastic Lymphoma KinaseIBA 01/2018 - 01/2018
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022
1	PlatinumIBA 01/2021
1	pembrolizumabIBA 01/2020
1	AlpelisibIBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020
1	Fulvestrant (Faslodex)FDA Link 01/2020
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2020
1	Hormones (Hormone)IBA 01/2020
1	Isoleucine (L-Isoleucine)FDA Link 01/2020
1	Leucine (L-Leucine)FDA Link 01/2020
1	Tamoxifen FDA LinkGeneric 01/2020
1	GTPase-Activating Proteins (GTPase-Activating Protein)IBA 01/2020
1	ras GTPase-Activating Proteins (ras-GAP)IBA 01/2020
1	Aromatase InhibitorsIBA 01/2020
1	Co-Repressor ProteinsIBA 01/2020
1	human ERBB2 proteinIBA 10/2019
1	pertuzumabIBA 10/2019
1	Transaminases (Aminotransferases)IBA 10/2019
1	taxaneIBA 10/2019
1	dabrafenibIBA 09/2019
1	trametinibIBA 09/2019
1	AfatinibIBA 01/2019
1	larotrectinibIBA 01/2019
1	osimertinibIBA 01/2019
1	palbociclibIBA 01/2019
1	CateninsIBA 01/2019
1	Pregnenolone Carbonitrile (PCN)IBA 01/2019
1	Androgen Receptors (Androgen Receptor)IBA 01/2019
1	LigandsIBA 12/2018
1	Phosphopyruvate Hydratase (Enolase)IBA 01/2018
1	NivolumabIBA 01/2018

Therapy/Procedure

27	Therapeutics 01/2022 - 01/2006
4	Precision Medicine 01/2020 - 01/2015
3	Drug Therapy (Chemotherapy) 01/2020 - 01/2018
2	Immunotherapy 12/2019 - 06/2019
1	Castration 01/2019
1	Molecular Targeted Therapy 11/2018
1	Lymph Node Excision (Lymph Node Dissection) 01/2018
1	Aftercare (After-Treatment) 01/2018